№ files_lp_4_process_2_54475
File format: docx
Character count: 15300
File size: 124 KB
School health procedure and individual healthcare plan template outlining responsibilities, medication arrangements, symptom response flowcharts, and coordination between parents, schools, and healthcare providers for pupils with severe allergies.
Document type:
School health procedure and individual healthcare plan template
Subject:
Severe allergies in pupils
Sector:
Education and school health services
Responsible organizations:
Schools; NHS; Royal Hospital for Sick Children; St John’s Hospital
Region:
West Lothian
Target group:
Pupils with diagnosed allergies
Participants:
Parents; school staff; healthcare professionals
Medical condition:
Severe allergy; food allergy; asthma (where applicable)
Required documentation:
Individual Healthcare Plan; Request for Use of Medication and/or Administration of Healthcare in School; Symptom and Action Flowcharts
Medication types:
Antihistamine; Salbutamol inhaler; Adrenaline pen
Healthcare coordination:
Parent; General Practitioner; hospital or allergy clinic
Medication management:
Parent-supplied medication in original packaging labelled with pupil’s name and dose
Plan review period:
At least annually; every three months in Early Learning and Childcare settings or at the start of a new term
School settings covered:
Early Learning and Childcare; Primary School; Secondary School; Special School
Key procedures:
Storage and accessibility of adrenaline pens; dietary control; curriculum adjustments; staff awareness of pupils with allergies
Personal data fields:
Pupil name; date of birth; CHI number; address; school; parent contacts; healthcare contacts
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2017
Version:
1.0
Date:
April 2017
Organization:
Department of Veterans Affairs, Office of Information and Technology (OI&T)
Product:
CTT & DM NDS Allergies Patch GMRA455
Related Applications:
VistA Adverse Reaction Tracking (ART) v.4.0; Computerized Patient Record System (CPRS) v.1.0; Kernel v.8.0
Patch Dependency:
XU8676
Document Type:
Deployment, Installation, Back-Out, and Rollback Guide
Deployment Method:
FORUM Patch Module; Kernel Installation Distribution System (KIDS)
Initial Deployment Site:
Central Plains HCS, Oklahoma City, OK
Deployment Scope:
All VA VistA instances running CPRS v.1.0 and ART v.4.0
Deployment Period:
Thirty days
Authors:
Mantech Mission Solutions and Services
Revision History:
Initial Draft December 18, 2016; Technical Writer Review December 19, 2016; Updates through April 2017
Year:
Not specified
Person:
Carla Hernandez
Subject:
Patient allergy data entry
Topic:
Electronic health records documentation
Document type:
Training scenario and procedural instructions
System / Platform:
EHRclinic
Medical category:
Drug allergy documentation
Allergy type:
Drug allergy
Allergy detail:
Codeine
Onset:
Adulthood
Recorded date and time:
September 10, 2010 - 12:00 am
Severity:
Severe
Status:
Active
Adverse reaction:
Breathing
Data source:
Patient intake sheet
Primary activity:
Adding allergy information to a patient face sheet
Target audience:
Medical students or healthcare trainees using EHRclinic
Year:
2026
Document type:
Medical consent form
Intended audience:
Parents or guardians of children
Child information included:
Name, date of birth, allergies
Medication details included:
Name, dose, administration times, start and stop dates, known side effects
Prescriber information included:
Name of prescribing health professional
Signatures required:
Parent/guardian, healthcare provider
Administration methods:
Oral, ear, eye, nebulizer, skin, other
Purpose:
Authorization for administration of medication to a child
Organisation:
Felixstowe Nursery School
Country:
England and Wales
Subject:
Health care and allergy management in early years education
Document type:
Institutional policy
Policy area:
Safeguarding and welfare requirement – health
Target group:
Nursery staff, parents, carers and visitors
Applicable setting:
Early years and preschool education environment
Regulatory references:
Managing Medicines in Schools and Early Years Settings (DCSF, March 2005); Food Information Regulation (2014)
Main risks addressed:
Food allergies, nut allergies, insect stings, animal allergies, anaphylaxis
Key medical treatments referenced:
Adrenalin auto-injectors (Epipen, Jext, Emerade)
Implementation measures:
Healthcare plans, risk assessments, staff training, allergen management procedures
Parent responsibilities:
Provide medical information, medication and emergency contacts
Staff responsibilities:
Allergy awareness, hygiene procedures, supervision of food activities, emergency response
Food safety practice:
Allergen information records and monitoring of snack ingredients
Year:
2026
Region:
Global
Topic:
Immunology / Nutrition
Document Type:
Scientific overview
Institution:
Medical research and clinical guidelines
Author:
Not specified
Target Audience:
Healthcare professionals, researchers, medical students
Allergy Mechanisms:
Ig-E mediated, Non Ig-E mediated
Common Allergens:
Peanuts, tree nuts, fish, soy, wheat, eggs, milk, shellfish, fruits, vegetables
Symptoms:
Cutaneous, gastrointestinal, respiratory, cardiovascular
Genetic Factors:
HLA-DQ locus, filaggrin, interleukin-10, STAT6, FOXP3
Enzyme Deficiencies:
Lactase, sucrose, isomaltase
Related Conditions:
Celiac disease, inflammatory bowel disease, migraine, food intolerance
Natural History:
Onset and resolution ages vary by allergen type
Endorsed Tests:
Ig-E antibody assays, clinical observation for non-Ig-E reactions
Classification:
Ig-E mediated Class 1 and Class 2 allergens
Pathogenesis Details:
Mast cell activation, cytokine release, T cell mediated inflammation
Clinical Manifestations:
FPIES, FPIAP, EoE, oral allergy syndrome, acute urticaria, atopic dermatitis
Note:
Year
Topic:
Food allergies, eczema
Document Type:
Patient Handout
Author:
Leah Lalor, Patricia Todd
Target Audience:
Parents of children with eczema
Expert Reviewer:
Vy Kim
Committee Reviewers:
Erin Mathes, Irene Lara-Corrales
Note:
Year
Subject:
Immigration and Refugee Status Verification
Document Type:
Guide
Document Type:
Clinical Guidelines
Authors:
Dr Bethan McMinn Consultant Community Paediatrician; Dr Klara Brzyska Paediatric ST4
Approval / Effective Date:
01/01/2023
Review Date:
01/01/2025
Version:
1
Target Audience:
People who need to know about this document in detail
Note:
Paediatricians (acute and community)
Disclaimer:
If the review date of this document has passed, please ensure that the version you are using is the most up to date version either by contacting the author.
Year:
2023
Region / City:
East Anglia, Wales
Theme:
Early Developmental Impairment, Intellectual Disability, Paediatric Assessment
Institution:
Cwm Taf Morgannwg University Health Board
Author:
Dr Bethan McMinn, Dr Klara Brzyska
Period of validity:
01/01/2023 - 01/01/2025
Approval Date:
01/01/2023
Year:
1998–2004
Region / City:
Baltimore, New York
Topic:
Communication, Special Education, Disability Support
Document Type:
Educational Guide / Reference
Institution / Organization:
Paul H. Brookes Publishing Co., Charles E. Merrill
Authors:
Downing, J.E.; Beukelman, D.R.; Mirenda, P.; Orelove, F.P.; Sobsey, D.; Snell, M.E.; Brown, F.
Target Audience:
Educators, Special Education Professionals
Period Covered:
Late 20th – early 21st century
Communication Types:
Receptive, Expressive, Symbolic, Nonsymbolic
Instructional Focus:
Strength-based approaches, observation skills, augmentative and alternative communication methods
Reference Systems:
Picture symbols, sign language, Braille, verbal speech, object cues, gestures, switch activation
Year:
2021
Region / City:
United Kingdom
Subject:
Health economics, antimicrobial evaluation
Document type:
Final report
Organization / Institution:
Centre for Health Economics, University of York; Health Economics and Decision Science, University of Sheffield
Author:
Sue Harnan, Ben Kearns, Alison Scope, Laetitia Schmitt, Dina Jankovic, Jean Hamilton, Ruth Wong, Tushar Srivastava, Harry Hill, Chu Chang Ku, Kate Ren, Claire Rothery, Laura Bojke, Mark Sculpher, Beth Woods
Target audience:
Healthcare professionals, policymakers, researchers
Period of validity:
2016 - ongoing
Approval date:
October 2021
Date of last modification:
October 2021
Year:
Not specified
Region / City:
North Northamptonshire
Topic:
Mental Health, Severe Mental Illness, Social Care
Document Type:
Request for Quotation (RFQ)
Organization / Institution:
North Northamptonshire Council
Author:
Not specified
Target Audience:
Potential suppliers
Effective Period:
Not specified
Approval Date:
Not specified
Date of Amendments:
Not specified
Canberra Health Services Guideline Apixaban and Rivaroxaban Use in Adults with Severe Kidney Disease
Year:
2021
Region / City:
Canberra, Australia
Topic:
Pharmacology / Kidney Disease
Document Type:
Clinical Guideline
Institution:
Canberra Health Services
Author:
Not specified
Target Audience:
Medical staff and pharmacists
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2017–2021
Medical field:
Sleep medicine
Condition:
Moderate to severe obstructive sleep apnea
Intervention:
Hypoglossal nerve stimulation
Procedure codes:
64582, 64583, 64584
Type of document:
Evidence review and policy summary
Reviewing bodies:
NICE; VbBS; HERC
Last review date:
November 2021
Study types included:
Systematic review; randomized controlled trial; prospective and retrospective case series
Number of studies:
7
Total patients:
326
Geographic context:
United Kingdom; United States
Regulatory context:
Clinical governance and payer policy assessment
Year:
2022
Region / City:
Australia
Subject:
Pharmacology, Pharmaceutical Benefits Scheme (PBS)
Document Type:
Submission
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Not specified
Target Audience:
Medical practitioners, healthcare professionals
Period of validity:
Not specified
Approval Date:
3 June 2022
Date of Changes:
Not specified
Contextual Description:
A regulatory submission detailing the request for listing of dupilumab in new forms for treating severe atopic dermatitis and uncontrolled severe asthma in pediatric patients under the PBS.
Year:
2025
Region / City:
UK
Topic:
Healthcare, Medication Guidelines
Document Type:
Medical Protocol
Organisation:
National Ambulance Service Medical Directors (NASMeD)
Author:
Dr. Elizabeth Miller, Dr. Dave Macklin, Mr. Andy Curran, Rosie England, Cathryn James, Dan Haworth, Tracy Rogers, Jo Jenkins, Rosie Furner
Target Audience:
Registered healthcare professionals, Paramedics, Nurses, Midwives
Effective Date:
May 2023
Review Date:
October 2025
Expiry Date:
April 2026
Approval Date:
May 2025
Change History:
Includes updates to drug administration protocols and clinical guidelines
Year:
2023
Region / City:
Australia
Topic:
Hidradenitis Suppurativa Treatment
Document Type:
Submission for Pharmaceutical Benefits Scheme (PBS) Listing
Organ / Institution:
Novartis Pharmaceuticals Australia Pty Limited
Author:
Novartis Pharmaceuticals Australia Pty Limited
Target Audience:
Medical professionals, Healthcare policymakers
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Amendments:
Not specified
Category / Program:
General Schedule (Code GE)
Prescriber Type:
Dental Medical Practitioners, Nurse Practitioners, Optometrists, Midwives
Restriction Type:
Authority Required
Severity:
Moderate to severe
Condition:
Hidradenitis suppurativa
Treatment Phase:
Initial treatment
Clinical Criteria:
Hurley stage II or III grading, abscess and inflammatory nodule count ≥ 3, failure to respond to antibiotics
Treatment Criteria:
Dermatologist supervision
Population Criteria:
Adult patients
Administrative Advice:
Subcutaneous injection
Prescribing Instructions:
Must assess disease severity, first 4 weeks under restriction
Cost:
$6,145.10 for 300 mg/2 mL pre-filled syringe/pen
Source:
Table 1.1, p25; Table 1.6, p35; Table 1.7, pp36-37; Table 1.7, p38
Year:
2019
Region / City:
United Kingdom
Topic:
Chronic Obstructive Pulmonary Disease (COPD), Oxygen Saturation
Document Type:
Guidance
Organization:
National Institute for Health and Care Excellence (NICE)
Author:
NICE
Target Audience:
General practitioners, healthcare professionals
Period of Validity:
Not specified
Approval Date:
August 2019
Date of Last Update:
N/A
Year:
2022-2023
Region / City:
Florida
Topic:
Education, Special Education, Accessibility
Document Type:
Official guideline
Organization:
Florida Department of Education (FLDOE)
Author:
Not specified
Target Audience:
Case managers, educators, IEP team members
Period of validity:
Ongoing, annual requests
Approval Date:
Not specified
Date of changes:
Not specified
Year:
2022
Region / City:
York
Theme:
Special Education, Curriculum Design
Document Type:
Educational Policy
Organization / Institution:
Applefields School
Author:
Applefields School Leadership Team
Target Audience:
Educators, Special Education Professionals, Parents of Students with Severe Learning Difficulties
Period of Validity:
Ongoing
Approval Date:
2022
Modification Date:
Ongoing
Year:
2017
Region / City:
Emergency Department
Topic:
Severe Sepsis, Septic Shock, Patient Rescreening
Document Type:
Advisory, Medical Alert
Institution:
UCLA
Author:
Not specified
Target Audience:
Emergency Department Nurses
Action Period:
3/3/17 – proposed changes
Approval Date:
Not specified
Modification Date:
3/24/17
Context:
A guideline for the early identification and rescreening of patients at risk for severe sepsis or septic shock in an emergency department setting, with detailed criteria for triggers and actions.